GenomeUp, the Italian startup leading the field of secure genetic data processing and management for the diagnosis of genetic diseases, has successfully closed a €4.5 million investment round. The funds raised will enable the company to accelerate its growth in the Italian market, expand internationally, and enhance JuliaOmix to support early cancer diagnosis and other applications based on omics big data—vast volumes of information generated from the integrated analysis of different omics research areas, such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics—providing deep insights into biological processes and a more accurate understanding of diseases.

The operation was led by The Techshop SGR, through the Techshop Primo fund, and subscribed by CDP Venture Capital through its Fondo Evoluzione and by Opes Italia, a Sicaf specializing in impact investments with positive social outcomes.

Thanks to this financial injection, GenomeUp accelerates its expansion plan, strengthening collaborations with centers of excellence in clinical genetics and laboratories, including the Bambino Gesù Pediatric Hospital in Rome, the Buzzi Pediatric Hospital in Milan, and the Venere Hospital in Bari, where a genomic screening was recently awarded.

GenomeUp's strategy aims to create an integrated digital infrastructure, connecting clinicians, laboratories, and hospitals in a single national network to make advanced diagnostics more accessible and efficient. This approach has been further consolidated by recent awards in the Tuscany and Veneto regions, the first building blocks of an innovative network destined to evolve into a national model serving patients and precision medicine.

Indeed, the competitive advantage of the JuliaOmix platform lies in its ability to connect various processes and stakeholders. It is a modular ecosystem designed to offer an end-to-end workflow for genetic diagnostics. From patient medical history to reporting, the platform integrates and optimizes every phase of the process, ensuring operational continuity and seamless genetic data management for clinicians and laboratories.

Currently, GenomeUp offers four complementary products:

• MED: Guides patient medical history and supports doctors in choosing the most appropriate genetic testing pathway.

• TRK: Manages sample tracking and workflow optimization at the laboratory level.

• CLD: Integrates with Next Generation Sequencing (NGS) machines to manage data storage and initial analysis.

• LAB: Completes the workflow by interpreting data and supporting geneticists in making diagnoses.

Since its inception, GenomeUp's software has tracked, reported, and stored over 2 petabytes of data on around 45,000 patients, managing over 18,000 sequencing processes in dozens of hospitals, genetic centers, and research laboratories, establishing itself as a strategic technology partner for both public and private healthcare sectors.

The growing demand for advanced solutions for genetic data analysis, tracking, reporting, and secure storage is driven by the decreasing costs of sequencing technology, the drive for genetic profiling of an increasing number of diseases, and the association of therapies aimed at personalization. GenomeUp meets this challenge with innovative solutions that drastically reduce the time needed for advanced diagnoses and optimize costs for all involved stakeholders.

The company, accelerated by Zest in 2018, envisions an ambitious growth plan that will quintuple its revenues over the next three years through an expansion strategy combining direct and indirect sales networks with distribution partnerships with strategic industry players such as Dedalus, Revvity, and Roche. The business model, based on a combination of SaaS and pay-per-use, offers clients maximum flexibility, ensuring scalable and effective adoption.

"This operation—explained Simone Gardini, CEO of GenomeUp—backed by leading investors, strengthens GenomeUp's leadership in the diagnostic big data management market. We are ready to bring our solution to the international stage, offering the only end-to-end platform capable of supporting doctors in diagnosing genetic diseases. It is essential to remember that behind every byte, there is a person—a patient with a unique and invaluable genetic heritage that we must protect from potential attacks."

“We are proud to invest in GenomeUp,” said Aurelio Mezzotero and Gianluca D’Agostino, Managing Partners of The Techshop. "We were impressed by the team's ambition and the passion with which the company is pursuing such an ethically important mission. The startup has managed to solve some highly complex scientific and technological challenges that currently hinder the efficiency of genetic laboratories. We foresee that, thanks to GenomeUp’s comprehensive and secure infrastructure, the hospitals and laboratories it serves will be able to place genetics at the heart of diagnosing many currently untreatable diseases, such as rare pediatric diseases and cancers."